Taysha Gene Therapies (TSHA) Total Liabilities (2019 - 2026)

Taysha Gene Therapies (TSHA) has 8 years of Total Liabilities data on file, last reported at $88.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 6.13% year-over-year to $88.4 million; the trailing twelve-month figure through Mar 2026 stood at $88.4 million (up 6.13% YoY), and the FY2025 full-year result was $96.4 million, up 8.49% from the prior year.
• Total Liabilities slipped to $88.4 million in Q1 2026, from $96.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $244.9 million in Q3 2023 to a low of $83.3 million in Q1 2025.
• A 5-year average of $108.8 million and a median of $97.8 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 477.5% in 2022 and plunged 62.67% in 2024, its largest moves.
• Tracing TSHA's Total Liabilities over 5 years: stood at $125.3 million in 2022, then decreased by 21.97% to $97.8 million in 2023, then decreased by 9.16% to $88.8 million in 2024, then gained by 8.49% to $96.4 million in 2025, then decreased by 8.27% to $88.4 million in 2026.
• Business Quant data shows TSHA's Total Liabilities at $88.4 million in Q1 2026, $96.4 million in Q4 2025, and $97.6 million in Q3 2025.